Christopher N Kaufmann1,2, Alison A Moore1,3, Mark W Bondi3,4, James D Murphy5, Atul Malhotra6, Laura A Hart7. 1. Division of Geriatrics and Gerontology, Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA. 2. Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla, CA. 3. Department of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA. 4. Veterans Affairs San Diego Healthcare System, La Jolla, CA. 5. Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, CA. 6. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA. 7. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA.
Abstract
PURPOSE OF REVIEW: Adverse effects of sedative-hypnotic medications on cognition are concerning. Past studies have examined benzodiazepine (BZD) use and cognitive outcomes; however, few studies have examined newer non-BZD hypnotic agents (nBHs; e.g. zolpidem). This systematic review examined observational studies assessing the association between nBH use and cognitive outcomes. RECENT FINDINGS: Five studies met eligibility requirements and were included in the review. Most studies did not find an association between nBH use and dementia diagnosis; however, we found no studies assessing other cognitive outcomes such as cognitive performance (e.g., word recall tasks). Characterization of nBH use mostly consisted of incident new use; one study assessed nBH dosing; none examined duration of use. Studies included were of strong quality. SUMMARY: This review found no association between nBH use and dementia diagnosis, although there is a need for more research on more cognitive outcomes and nBH use patterns.
PURPOSE OF REVIEW: Adverse effects of sedative-hypnotic medications on cognition are concerning. Past studies have examined benzodiazepine (BZD) use and cognitive outcomes; however, few studies have examined newer non-BZD hypnotic agents (nBHs; e.g. zolpidem). This systematic review examined observational studies assessing the association between nBH use and cognitive outcomes. RECENT FINDINGS: Five studies met eligibility requirements and were included in the review. Most studies did not find an association between nBH use and dementia diagnosis; however, we found no studies assessing other cognitive outcomes such as cognitive performance (e.g., word recall tasks). Characterization of nBH use mostly consisted of incident new use; one study assessed nBH dosing; none examined duration of use. Studies included were of strong quality. SUMMARY: This review found no association between nBH use and dementia diagnosis, although there is a need for more research on more cognitive outcomes and nBH use patterns.
Authors: Christopher N Kaufmann; Adam P Spira; G Caleb Alexander; Lainie Rutkow; Ramin Mojtabai Journal: Pharmacoepidemiol Drug Saf Date: 2015-12-29 Impact factor: 2.890
Authors: Rajaa Lagnaoui; Bernard Bégaud; Nicholas Moore; Anicet Chaslerie; Annie Fourrier; Luc Letenneur; Jean François Dartigues; Yola Moride Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437